San Diego, CA -- (SBWire) -- 03/12/2020 --An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Outlook Therapeutics, Inc.
Investors who purchased shares of Outlook Therapeutics, Inc. (NASDAQ: OTLK) and currently hold any of those NASDAQ: OTLK shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Outlook Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
Cranbury, NJ based Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. reported that its Total Revenue rose from $.3088 million for the 12 months period that ended on September 30, 2018 to $8.146 million for the 12 months period that ended on September 30, 2019 and that its Net Loss for those respective time periods increased from $30.09 million to $34.52 million.
Shares of Outlook Therapeutics, Inc. (NASDAQ: OTLK) declined from $10.80 per share in February 2019 to as low as $0.52 per share in late 2019.
On March 11, 2020, NASDAQ: OTLK shares closed at $0.66 per share.
Those who purchased shares of Outlook Therapeutics, Inc. (NASDAQ: OTLK), have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
NASDAQ: OTLK Investor Alert: Investigation over Potential Wrongdoing at Outlook Therapeutics, Inc.
An investigation on behalf of investors in Outlook Therapeutics, Inc. (NASDAQ: OTLK) shares over potential wrongdoing at Outlook Therapeutics, Inc. was announced.